HERG and KvlQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers

Molecular Pharmacology

Volumn 54, Issue 4, 1998, Pages 695-703

  Chouabe, Christophe ^a   Drici, Milou Daniel ^a   Romey, Georges ^a   Barhanin, Jacques ^a   Lazdunski, Michel ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; MIBEFRADIL; NITRENDIPINE; POTASSIUM CHANNEL; VERAPAMIL;

ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL;

ANIMALS; BENZIMIDAZOLES; BEPRIDIL; CALCIUM CHANNEL BLOCKERS; CLONING, MOLECULAR; COS CELLS; HEART; ION CHANNEL GATING; LONG QT SYNDROME; MEMBRANE POTENTIALS; MIBEFRADIL; POTASSIUM CHANNELS; TETRAHYDRONAPHTHALENES; TRANSFECTION; VERAPAMIL;

EID: 0031752779     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Attali B (1996) A new wave for heart rhythms. Nature (Lond) 384:24-25.
2. Balser JR, Bennett PB, Hondeghem LM, and Roden DM (1991) Suppression of time-dependent outward current in guinea pig ventricular myocytes: actions of quinidine and amiodarone. Circ Res 69:519-529.
3. Ks cardiac potassium current. Nature (Lond) 384:78-80.
4. Billman GE and Hamlin RL (1996) The effects of mibefradil, a novel calcium channel antagonist, on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. J Pharmacol Exp Ther 277:1517-1526.
5. Campbell RM, Woosley RL, Iansmith DHS, and Roden DM (1990) Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. PACE 13:30-36.
6. CAST (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321:406-412.
7. + channel mutations in Romano-Ward and Jervell and Lange-Nielsen inherited cardiac arrhythmias. EMBO (Eur Mol Biol Organ) J 16:5472-5479.
8. Clozel JP, Ertel EA, and Ertel SI (1997) Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens 15:S17-S25.
9. Cosio FG, Goicolea A, Lopez GM, Kallmeyer C, and Barroso JL (1991) Suppression of torsades de pointes with verapamil in patients with atrio-ventricular block. Eur Heart J 12:635-638.
10. DAVIT (1990) Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 66:779-785.
11. + channel block by verapamil and related compounds in rat alveolar epithelial cells. J Gen Physiol 106:745-779.
12. Gill JS, Blaszyk K, Ward DE, and Gamm AJ (1993) Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. Am Heart J 126:1126-1133.
13. Gulamhusein S, Ko P, and Klein GJ (1983) Ventricular fibrillation following verapamil in the Wolff-Parkinson-White syndrome. Am Heart J 106:145-147.
14. Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ (1981) Improved patch-clamp techniques for high resolution current recording from cells and cell-free membranes patches. Eur J Physiol 391:85-100.
15. Hosey MM and Lazdunski M (1988) Calcium channels: molecular pharmacology, structure and regulation. J Membr Biol 104:81-105.
16. + channels. J Pharmacol Exp Ther 234:134-140.
17. Jurman ME, Boland LM, and Yellen G (1994) Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. Biotechniques 17:876-881.
18. Lauer MR, Liem LB, Young C, and Sung RJ (1992) Cellular and clinical electrophysiology of verapamil-sensitive ventricular tachycardias. J Cardiovasc Electrophysiol 3:500-514.
19. Lee KL, Lauer MR, Young C, Lai W-T, Tai Y-T, Hingson C, Liem LB, and Sung RJ (1996) Spectrum of electrophysiologic and electropharmacologic characteristics of verapamil-sensitive ventricular tachycardia in patients without structural heart disease. Am J Cardiol 77:967-973.
20. + current in human ventricular myocytes. Circ Res 78:689-696.
21. Loussouarn G, Charpentier F, Mohammad-Panah R, Kunzelmann K, Baro I, and Escande D (1997) KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethylchromane. Mol Pharmacol 52:1131-1136.
22. Manouvrier J, Sagot M, Carson C, Vasklamm G, Leroy R, Reade R, and Dacloux G (1986) Nine cases of torsades de pointes with bepridil administration. Am Heart J 5:1005-1007.
23. Massie BM (1997) Mibefradil: a selective T-type calcium antagonist. Am J Cardiol 80:231-321.
24. Napolitano C, Priori S, and Schwartz P (1994) Torsade de pointes: mechanism and management. Drugs 47:51-65.
25. Nattel S, Talajic M, Fermini B, and Roy D (1992) Amiodarone: pharmacology, clinical actions, and relationships between them. J Cardiouasc Electrophysiol 3:266-280.
26. + current in small-cell lung cancer cells. J Pharmacol Exp Ther 257:184-191.
27. Pinto JV, Ramani K, Neelagaru S, Kown M, and Gheorghiade M (1997) Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. Prog Cardiovasc Dis 40:85-93.
28. + channel cloned from human heart. Mol Pharmacol 44:642-648.
29. Rauer H and Grissmer S (1996) Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3. Mol Pharmacol 50:1625-1634.
30. Roden DM (1996) Antiarrhythmic drugs, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE, eds), 9th ed, pp 839-874, McGraw-Hill, New York.
31. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, and Vincent GM (1996) Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions. Circulation 94:1996-2012.
32. Salata JJ and Brooks RR (1997) Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiouasc Drug Rev 15:137-156.
33. Ks. Am J Physiol 271:H2477-H2489.
34. Ks potassium channel. Nature (Lond) 384:80-83.
35. Kr potassium channel. Cell 81:299-307.
36. + current: differential sensitivity to block by class-III antiarrhythmic agents. J Gen Physiol 96:195-215.
37. Singh BN (1989) When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 63:867-869.
38. Snyders DJ and Chaudhary A (1996) High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 49:949-955.
39. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, and Veltri EP (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: the SWORD investigators. Survival With Oral d-Sotalol. Lancet 348:7-12.
40. Yatani A, Brown AM, and Schwartz A (1986) Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther 237:9-17.